Diagnostyka S.A. (WSE:DIA)
Poland · Delayed Price · Currency is PLN | Market Cap | 5.37B -12.2% |
| Revenue (ttm) | 2.58B +19.2% |
| Net Income | 254.88M +6.2% |
| EPS | 7.55 +6.2% |
| Shares Out | 33.76M |
| PE Ratio | 21.06 |
| Forward PE | 17.75 |
| Dividend | 4.40 (2.77%) |
| Ex-Dividend Date | Jun 1, 2026 |
| Volume | 43,689 |
| Open | 159.00 |
| Previous Close | 159.00 |
| Day's Range | 158.30 - 159.90 |
| 52-Week Range | 146.40 - 208.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 196.39 (+23.52%) |
| Earnings Date | Nov 26, 2026 |
About Diagnostyka
Diagnostyka S.A. provides diagnostic services in Poland. The company operates as a medical laboratory, which offers services, such as ultrasound, X-ray, computed tomography, and magnetic resonance imaging. It also offers specialized research in the field of microbiology, autoimmunity, toxicology, and molecular biology, as well as human genome research, histopathological examinations, immunohistochemical tests, cytological tests, and cytogenetic tests. The company provides services to individual clients, and public and private entities. Diagnost... [Read more]
Financial Performance
In 2025, Diagnostyka's revenue was 2.41 billion, an increase of 23.60% compared to the previous year's 1.95 billion. Earnings were 251.60 million, an increase of 12.66%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for DIA stock is "Buy." The 12-month stock price target is zł 196.39, which is an increase of 23.52% from the latest price.
News
Diagnostyka Earnings Call Transcript: Q2 2026
Revenue grew 16% year-on-year in H1 2026, with strong B2B and preventive program contributions. EBITDA margin remained robust, and guidance for 2026 is unchanged despite higher costs from salary hikes and SAP implementation. Eight acquisitions and a new clinical trials segment signal ongoing expansion.
Diagnostyka Quarterly report: Q2 2026
Diagnostyka has published its Q2 2026 quarterly earnings report on September 11, 2026.
Diagnostyka Slides: Q2 2026
Diagnostyka has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on September 11, 2026.
Diagnostyka Quarterly report: Q1 2026
Diagnostyka has published its Q1 2026 quarterly earnings report on May 29, 2026.
Diagnostyka Slides: Q1 2026
Diagnostyka has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 29, 2026.
Diagnostyka Earnings Call Transcript: Q4 2025
Revenue grew 23.6% year-over-year, driven by strong B2B and public health program growth, with EBITDA up 15% and net profit up nearly 13%. Regulatory changes in DI and SAP implementation pose short-term challenges, but stable margins and robust cash flow support continued investment and dividends.
Diagnostyka Annual report: Q4 2025
Diagnostyka has published its Q4 2025 annual report on April 21, 2026.
Diagnostyka Slides: Q4 2025
Diagnostyka has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on April 21, 2026.
Diagnostyka Earnings Call Transcript: Q3 2025
Q3 2025 saw revenue up 26% year-on-year and recurring EBITDA over PLN 150 million, driven by higher test volumes, price increases, and diagnostic imaging. Strong cash flow and robust financials support ongoing acquisitions and innovation, with stable outlook and dividend policy.
Diagnostyka Quarterly report: Q3 2025
Diagnostyka has published its Q3 2025 quarterly earnings report on November 20, 2025.
Diagnostyka Slides: Q3 2025
Diagnostyka has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 20, 2025.